Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 14/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26917340 | 0.83 | PDGFRB (0.63) | PDGFRBKDRFYNMAP4K4 | |
| SCHEMBL29858130 | 0.83 | PDGFRB (0.63) | PDGFRBKDRFYNMAP4K4 | |
| SCHEMBL22820405 | 0.81 | PDGFRB (0.60) | PDGFRBKDRCHEK2FYN | |
| SCHEMBL17668232 | 0.80 | KDR (1.00) | PDGFRBKDRFYNMAP4K4 | |
| SCHEMBL22820659 | 0.79 | PDGFRB (0.60) | PDGFRBKDRCHEK2FYNMKNK1 | |
| SCHEMBL17339011 | 0.78 | LIPG (0.46) | PDGFRBKDRMKNK1 | |
| SCHEMBL22820663 | 0.77 | PDGFRB (0.55) | PDGFRBKDRFYN | |
| SCHEMBL22554252 | 0.76 | PDGFRB (0.50) | PDGFRBKDRCHEK2 | |
| SCHEMBL16680010 | 0.76 | PDGFRB (0.57) | PDGFRBKDR | |
| SCHEMBL476916 | 0.75 | F11 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153804-B2 | Aryl pyridines and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153804-B2 | Aryl pyridines and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20070032501-A1 | Aryl pyridines and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-02-08 | — | — | US | disclosed |
| US-20070032501-A1 | Aryl pyridines and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-02-08 | — | — | US | disclosed |
| WO-2007016674-A2 | 2-AMINOARYL PYRIDINES AS PROTEIN KINASES INHIBITORS | LEXICON GENETICS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032501-A1 | Aryl pyridines and methods of their use | PNPO, PAH, AHR | PDGFRB 2128/4885KDR 4725/4885CHEK2 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.